主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE ›› 2021, Vol. 44 ›› Issue (3): 272-279.doi: 10.3969/j.issn.1006-2157.2021.03.013

• Clinical Studies • Previous Articles     Next Articles

Clinical efficacy and safety observation of Luofengning Formula II Granules in the treatment of patients with chronic heart failure and diuretic resistance*

Yang Xueqing1, Wang Xian2#   

  1. 1 Department of Cardiovascular Medicine, Beijing Hospital of Traditional Chinese Medicine in Shunyi, Beijing 101300, China;
    2 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
  • Received:2020-10-08 Online:2021-03-30 Published:2021-03-30
  • Contact: Prof. Wang Xian, Ph.D., Chief Physician, Doctoral Supervisor. Dongzhimen Hospital, Beijing University of Chinese Medicine. No.5 Haiyuncang Street, Dongcheng District, Beijing 100700. E-mail: wx0515@hotmail.com
  • Supported by:
    National Natural Science Foundation of China (No. 82074263), Research Cultivation Program of Beijing Municipal Hospitals (No.PZ2019025) Ethical review: Medical Ethics Committee of Beijing Hospital of Traditional Chinese Medicine in Shunyi (No.2019SYKY12-01)

Abstract: Objective To investigate clinical efficacy and safety of Luofengning (Collateral-Wind-Calming) Formula II Granules (LFNFIIG) in the treatment of patients with chronic heart failure with diuretic resistance. Methods 70 patients with chronic heart failure and diuretic resistance were randomly divided into the treatment group (n=35) and the control group (n=35). Parameters such as 24-hour urine volume, body weight, plasma levels of NT-proBNP, typical heart failure symptom quantitative score, Torasemide dosage, efficacy evaluation standard of patients with heart failure, and electrolyte, liver and kidney function and other safety parameters were used to appraise the clinical efficacy and safety before and after 2 weeks of treatment respectively. There was no significant difference in the 24-hour urine volume, body weight and plasma NT proBNP levels between the two groups before treatment (P> 0.05). Results After 2 weeks of treatment, the 24-hour urine volume, body weight, plasma levels of NT-proBNP of two groups were improved with statistical significance (P<0.01 or P<0.05) compared with before treatment. After treatment, the 24-hour urine volume of treatment group was higher than that of the control group and the plasma level of NT-proBNP and weight of the treatment group were significantly lower than those of the control group (P<0.05). There was no significant difference in the total effective rate between the two groups (P> 0.05), but the treatment group demonstrated better efficacy. After treatment, edema and oliguria of the treatment group were reduced obviously (P<0.05) compared with the control group. However, the other self-reported symptoms of the treat group were not significantly improved, and the differences between the two groups were not statistically significant (P> 0.05). After treatment, the dosage of torasemide used by the two groups was significantly lower than that before treatment (P<0.01) and torasemide dosage of the treatment group was significantly lower than that of the control group (P<0.05). After treatment, safety parameters such as Cr and Na+ of the treatment group were better than those of the control group and the difference was statistically significant (P<0.05). Conclusion LFNFIIG can improve the diuretic resistance and heart function of patients without side effects and with a good safety profile during the treatment.

Key words: Luofengning Formula II Granules, chronic heart failure, diuretic resistance

CLC Number: 

  • R256.2